Health
Roche’s Columvi combination shows sustained survival benefit at three-year follow up of pivotal phase III STARGLO study
Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx1This Columvi combination is available off-the-shelf and could offer a potentially curative treatment option for people with R/R DLBCL who are not candidates for transplantColumvi in combination with GemOx has now been approved in more than 50 countries worldwide and recommended in international treatment guidelines2-4 Basel, 8 December 2025 - Roche (SIX: RO, ROG; OTCQX:
About this update from Roche Holding Ltd
[{"type":"image","alt":"F. Hoffmann-La Roche Ltd","displaySize":"","headline":null,"caption":"F. Hoffmann-La Roche Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TdqKHuoAMRswPfW7YQ22wg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d295bae68c32358ba6ac888e76c1cca2","width":300,"height":198}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Overall survival was twice as long for people treated with Columvi in combination with GemOx versus MabThera/Rituxan plus GemOx1","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"This Columvi combination is available off-the-shelf and could offer a potentially curative treatment option for people with R/R DLBCL who are not candidates for transplant","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Columvi in combination with GemOx has now been approved in more than 50 countries worldwide and recommended in international treatment guidelines2-4 ","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":447,"olType":false},{"type":"text","content":"Basel, 8 December 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today three-year follow-up data from the pivotal phase III STARGLO study in people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant (ASCT). After a median follow-up of 35.1 months, overall survival (OS) remained twice as long for people treated with Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) versus MabThera®/Rituxan® (rituximab) plus GemOx (R-GemOx) (25.5 months versus 12.5 months, respectively [hazard ratio (HR)=0.60, 95% confidence interval (CI): 0.43-0.8]).1 Results were presented at the 67th American Society of Hematology Annual Meeting and Exposition, 6-9 December 2025 in Orlando, Florida, US.","length":850,"tagName":"p"},{"type":"text","content":"Subgroup analyses showed consistent results across clinically relevant subgroups of prior line of therapy and age.1 The greatest efficacy benefit was seen in people who had received on...